Allergy Therapeutics' share price tumbled yesterday after announcing it had halted its manufacturing in the UK following an internal review of its operating processes. Shares closed down almost eight per cent yesterday afternoon. The recent losses weigh on an ongoing trend into the red, with the stock having lost more than half of its value over the past year. The London-listed biotechnology company, which makes products for pollen, pet and mould allergies, announced the temporary move at its site in Worthing and said was undergoing improvements to the production process. CEO Manuel Llobet called the pause in production "necessary" and assured that the move "does not affect the safety of our products".

(c) 2022 City A.M., source Newspaper